<DOC>
	<DOCNO>NCT00133731</DOCNO>
	<brief_summary>The objective dose-ranging study determine effect several intravenous ( IV ) regimens otamixaban pharmacodynamic marker ( include marker thrombosis coagulation marker ) , safety/tolerability , clinical efficacy pharmacokinetics .</brief_summary>
	<brief_title>The SEPIA-PCI Trial : Otamixaban Comparison Heparin Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>18 year age old Due undergo nonurgent percutaneous coronary intervention ( PCI ) Planned treatment aspirin clopidogrel Recent acute coronary syndrome Patients risk , prior recent , bleed Patients receive recent prior treatment anticoagulant Creatinine clearance &gt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>